RO5479599
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for RO5479599, covering 2017-01-25 to 2017-01-27. Get the full timeline:
Most recent: Clinical Trial Update: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin [Phase 1]